Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma

被引：0
|
作者：
Gay, Francesca [1 ]
Hayman, Suzanne [1 ]
Lacy, Martha Q. [1 ]
Buadi, Francis [1 ]
Gertz, Morie A. [1 ]
Kumar, Shaji [1 ]
Dispenzieri, Angela [1 ]
Mikhael, Joseph R. [2 ]
Bergsagel, Leif [2 ]
Dingli, David [1 ]
Reeder, Craig B. [2 ]
Lust, John A. [1 ]
Russel, Stephen [1 ]
Roj, Vivek [3 ]
Zeldenrust, Steven R. [1 ]
Witzig, Thomas E. [1 ]
Fonseca, Rafael [2 ]
Kyle, Robert [1 ]
Greipp, Philip R. [1 ]
Stewart, A. Keith [2 ]
Rajkumar, S. Vincent [1 ]
机构：
[1] Mayo Clin, Coll Med, Div Hematol, Rochester, MN USA
[2] Mayo Clin Scottsdale, Div Hematol Oncol, Coll Med, Scottsdale, AZ USA
[3] Mayo Clin, Coll Med, Div Hematol Oncol, Jacksonville, FL 32224 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1494 / 1495
页数：2
相关论文
共 50 条
  • [1] Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma
    Mark, Tomer M.
    Bowman, Isaac A.
    Rossi, Adriana C.
    Shah, Manan
    Rodriguez, Melissa
    Quinn, Ryann
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Jayabalan, David
    Ely, Scott
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    [J]. LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2842 - 2849
  • [2] EFFECT OF THALIDOMIDE-DEXAMETHASONE THERAPY ON BONE MARROW ANGIOGENESIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Ladeb, S.
    Mrad, K.
    Abdelkefi, A.
    Torjemane, L.
    Safra, I.
    Hdiji, S.
    Ben Romdhane, N.
    Mdhaffer, M.
    El Omri, H.
    Ben Othman, T.
    Ben Romdhane, K.
    Ben Abdeladhim, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 512 - 512
  • [3] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Khan, Meaghan L.
    Reeder, Craig B.
    Kumar, Shaji K.
    Lacy, Marthy Q.
    Reece, Donna E.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Phillip
    Hayman, Suzanne
    Zeldenhurst, Steven
    Dingli, David
    Lust, John
    Russell, Stephen
    Laumann, Kristina M.
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Rajkumar, S. Vincent
    Stewart, A. Keith
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
  • [4] Prognostic Impact of the Plasma Cell Labeling Index (LI) in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Dexamethasone (Thal/Dex) or Lenalidomide-Dexamethasone (Len/Dex)
    Kapoor, Prasw Nt
    Kumar, Shaji
    Greipp, Philip R.
    Laumann, Kristina M.
    Mandrekar, Sumithra
    Rajkumar, S. Vincent
    Witzig, Thomas E.
    [J]. BLOOD, 2008, 112 (11) : 609 - 609
  • [5] Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Gay, Francesca
    Hayman, Suzanne R.
    Lacy, Martha Q.
    Buadi, Francis
    Gertz, Morie A.
    Kumar, Shaji
    Dispenzieri, Angela
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Dingli, David
    Reeder, Craig B.
    Lust, John A.
    Russell, Stephen J.
    Roy, Vivek
    Zeldenrust, Steven R.
    Witzig, Thomas E.
    Fonseca, Rafael
    Kyle, Robert A.
    Greipp, Philip R.
    Stewart, A. Keith
    Rajkumar, S. Vincent
    [J]. BLOOD, 2010, 115 (07) : 1343 - 1350
  • [6] Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
    Liang, Dong
    Bai, Shenrui
    Feng, Demei
    Chen, Guanjun
    Liang, Yang
    Wang, Hua
    [J]. BMC CANCER, 2024, 24 (01)
  • [7] CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (CTD) AS INITIAL THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Vasquez, J.
    Ruiz, R.
    Aliaga, K.
    Valencia, F.
    Enriquez, D.
    Palacios, V.
    Quintana, S.
    Casanova, L.
    [J]. HAEMATOLOGICA, 2016, 101 : 798 - 798
  • [8] Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma
    Wang, M
    Weber, DM
    Delasalle, K
    Alexanian, R
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (03) : 194 - 197
  • [9] Initial therapy with thalidomide/dexamethasone versus lenalidimide/dexamethasone in newly diagnosed multiple myeloma: A retrospective analysis of two phase II trials
    Nowakowski, G. S.
    Lacy, M. Q.
    Gertz, M. A.
    Dispenzieri, A.
    Dingli, D.
    Greipp, P. R.
    Kumar, S.
    Geyer, S.
    Fonseca, R.
    Vivek, R.
    Hayman, S.
    Lust, J. A.
    Kyle, R. A.
    Witzig, T. E.
    Rajkumar, S. V.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 179 - 179
  • [10] Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
    Richardson, Paul G.
    Hofmeister, Craig C.
    Rosenbaum, Cara A.
    Htut, Myo
    Vesole, David H.
    Berdeja, Jesus G.
    Liedtke, Michaela
    Chari, Ajai
    Smith, Stephen D.
    Lebovic, Daniel
    Raje, Noopur
    Byrne, Catriona
    Liao, Eileen
    Gupta, Neeraj
    Di Bacco, Alessandra
    Estevam, Jose
    Berg, Deborah
    Baz, Rachid
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 231 - 244
12345